Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Magné

Showing results (71-80 of 97) with videos related to

Pageof 10
Sort By:
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|February 28, 2012
[Magnetic resonance imaging for delineation of prostate in radiotherapy: monocentric experience and review of literature]P Auberdiac, C Chargari, F Négrier, et al.
Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique|April 1, 2011
[Benefit of a prolonged adjuvant treatment with temozolomide for the management of patients with glioblastoma]N Malkoun, M-J Fotso, L Cartier, et al.
Bulletin Du Cancer|January 21, 2010
Coexpression of biological key modulators in primary colorectal carcinomas and related metastatic sites: implications for treatment with cetuximabA Barbier, J Domont, N Magné, et al.
Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique|May 23, 2019
[Use of 4D-CT: Main technical aspects and clinical benefits]A Rehailia-Blanchard, S De Oliveira Duarte, M Baury, et al.
European Journal of Cancer (Oxford, England : 1990)|June 23, 2009
Phase 1 dose-escalation study of oral tyrosine kinase inhibitor masitinib in advanced and/or metastatic solid cancersJ C Soria, C Massard, N Magné, et al.
British Journal of Cancer|July 31, 2003
Molecular mechanisms underlying the interaction between ZD1839 ('Iressa') and cisplatin/5-fluorouracilN Magné, J-L Fischel, C Tiffon, et al.
Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique|July 25, 2016
[Radiotherapy phase I trials' methodology: Features]R Rivoirard, A Vallard, J Langrand-Escure, et al.
Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique|March 30, 2016
Conflict of interests for radiation oncologists: Harnessing disclosures from policy to realityJ-B Guy, A Vallard, S Espenel, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|June 30, 2022
Cost-effectiveness of hypofractionated versus conventional radiotherapy in patients with intermediate-risk prostate cancer: An ancillary study of the PROstate fractionated irradiation trial - PROFITK Zhou, M Renouf, G Perrocheau, et al.
Radiation Oncology (London, England)|July 19, 2017
Biomarkers of resistance to radiation therapy: a prospective study in cervical carcinomaP Moreno-Acosta, A Vallard, S Carrillo, et al.
Pageof 10

Showing results (71-80 of 97) with videos related to

Sort By:
Pageof 10
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|February 28, 2012
[Magnetic resonance imaging for delineation of prostate in radiotherapy: monocentric experience and review of literature]P Auberdiac, C Chargari, F Négrier, et al.
Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique|April 1, 2011
[Benefit of a prolonged adjuvant treatment with temozolomide for the management of patients with glioblastoma]N Malkoun, M-J Fotso, L Cartier, et al.
Bulletin Du Cancer|January 21, 2010
Coexpression of biological key modulators in primary colorectal carcinomas and related metastatic sites: implications for treatment with cetuximabA Barbier, J Domont, N Magné, et al.
Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique|May 23, 2019
[Use of 4D-CT: Main technical aspects and clinical benefits]A Rehailia-Blanchard, S De Oliveira Duarte, M Baury, et al.
European Journal of Cancer (Oxford, England : 1990)|June 23, 2009
Phase 1 dose-escalation study of oral tyrosine kinase inhibitor masitinib in advanced and/or metastatic solid cancersJ C Soria, C Massard, N Magné, et al.
British Journal of Cancer|July 31, 2003
Molecular mechanisms underlying the interaction between ZD1839 ('Iressa') and cisplatin/5-fluorouracilN Magné, J-L Fischel, C Tiffon, et al.
Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique|July 25, 2016
[Radiotherapy phase I trials' methodology: Features]R Rivoirard, A Vallard, J Langrand-Escure, et al.
Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique|March 30, 2016
Conflict of interests for radiation oncologists: Harnessing disclosures from policy to realityJ-B Guy, A Vallard, S Espenel, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|June 30, 2022
Cost-effectiveness of hypofractionated versus conventional radiotherapy in patients with intermediate-risk prostate cancer: An ancillary study of the PROstate fractionated irradiation trial - PROFITK Zhou, M Renouf, G Perrocheau, et al.
Radiation Oncology (London, England)|July 19, 2017
Biomarkers of resistance to radiation therapy: a prospective study in cervical carcinomaP Moreno-Acosta, A Vallard, S Carrillo, et al.
Pageof 10